Life Sciences Archive » September, 2016

Life Sciences - September, 2016

342 articles

• J&J Faces Hip MDL Trial Amid Series Of Pro-Plaintiff Rulings
• Depomed Gets Patent Win Over Generic Nucynta Drugmakers
• DOJ Says Execs' Convictions Unrelated To Free Speech
• Time Clocks Improve Patent Trials, Litigators Say
• Patent Trial Judges Oppose Posner's Push For Neutral Experts
• Ex-Pharma Co. CEO Indicted Over $100M Fraud Scheme
• Hospira Can't Escape Contract Claims In GSK Vaccine Suit
• Patients Blast Cook's Bellwether Pick In Vein Filter MDL
• Momenta, Sandoz Can't Beat Blood Clot Drug Monopoly Suit
• Walgreen Escapes Most Of Investor Suit Over Alliance Buy
• GlaxoSmithKline To Pay $20M SEC Fine Over China Bribery
• Del. Judge Denies Quick Wins In Device Co.'s Coverage Battle
• Par Sues FDA For Yanking Gout Drug's 180-Day Exclusivity
• Teva Knocks Out FCPA Probe Retaliation Suit
• Adare, Teva Say Apotex Infringed Patent With Amrix Generic
• Co.'s E. Coli, Salmonella Losses Aren't Covered, Underwriters Say
• Charitable Donations And FCPA Risks: Lessons From Nu Skin
• Fed. Circ. On-Sale Bar Case Could Make Axing Patents Harder
• Oral Advocacy And 'Vocal Fry'
• $200K Fee Request Questioned In Mooted Class Case
• Drug Cos. Lose Bid to Stay Chicago's Opioid Marketing Suit
• SEC, DOJ Accuse Ex-Drug Exec Of Insider Trading Scheme
• IRS Gets Win In $24M Fight With Abbott Exec's Estate
• LivaNova Escapes Suit Over Blood Temp Equipment
• Insurer Needn't Cover $5M HIPAA Probe Costs, 9th Circ. Told
• Express Scripts Gets $65M In Horizon Rebate Breach Deal
• Ex-Insys Manager Charged In Fentanyl Kickback Scheme
• Bankrupt Firm's Execs Can't Dodge Breach Of Duty Suit
• 3 Cos. Price IPOs Totaling $329M At Bottom Or Below Range
• Ohio Surgery Center Loses Bid To Escape FCA Spat
• Bristol-Myers Wants Abilify Gambling Suits Sent To Florida
• Grouping J&J Suits Poses Delays For Terminally Ill, JPML Told
• Real Estate Rumors: Madison, Pineapple Grove, Lonza
• Atty Dodges DQ, But Has Witness Statements Trashed
• 5 Tips For Preparing Sales Reps For Trial Examination
• 2nd Circ. Creates Confusion For FDA-Vetted Marketers
• Suit Over Weak IVF Drug Survives Dismissal Bid
• Benicar MDL Plaintiffs Can't Depose Foreign Witnesses
• Patients Urge Same Schedule For 3 Trials In Vein-Filter MDL
• Boehringer Can Hide Emails In FTC Pay-For-Delay Suit
• 'Unicorn' Nutanix Raises IPO Target Price
• Biopharm, Fee Cases Nixed In Del. Nod To Calif. Forum Pick
• Merck Stays Clear Of Ex-Worker's Sex Bias Claim
• Squire Draws Tokyo Arbitration, Life Sci Pro From K&L Gates
• Pharmacy Exec Wants Civil Docs In Meningitis Murder Trial
• Sens. Ask DOJ If Mylan's EpiPen Rebates Violate FCA
• The Courtroom Where It Happened: Hamilton As A Lawyer
• Congress Reaches Deal To Avoid Gov't Shutdown
• Mylan Antitrust Suit Over Acne Drug Rejected By 3rd Circ.
• 5th Circ. Upholds Video Testimony In J&J Hip MDL
• International Comity Saves Vitamin C Defendants
• Why Have Lawyers Forgotten About The Middle Class?
• Ethicon Says Rival's Suit An Attempt To Nix Poaching Claims
• Teva Alleges Fraud In $2B Purchase Of Mexican Drug Co.
• Pharma Co. Linked To Ex-Gov. McDonnell Scandal Hits Ch. 7
• And Now A Word From The Panel: 3 Alternatives To MDLs
• Pa. Appeals Court Urged To Junk Risperdal Time Bar
• Bayer Hits BASF With Suit Over Herbicide Patent
• FDA Warning Wire: Sketchy SuperValu Seafood, Tainted Drugs
• Medical Implant Co. Can't Secure Defamation Coverage
• Sales Rep Wants Docs Public In $40B Celgene FCA Row
• Drugmakers Tell 3rd Circ. To Punt Effexor To Fed. Circ.
• Deals Rumor Mill: Blue Apron, Dick Clark Productions, Bayer
• EcoMed Says Japanese Co. Breached $22M Distribution Pact
• Genetic Info Firm Nabs $45M From Bono, Private Investors
• Lipitor Buyers Ask 3rd Circ. To Keep Pay-For-Delay Fight
• The Role Of Value And Cost In Prescription Drug Pricing
• Advanced Disposal 1 Of 4 IPO Launches Totaling $745M
• 'Natural' Menopause Drug Deception Suit Survives Dismissal
• Anticipating And Avoiding Expert Deposition Fee Disputes
• House OKs Bill Broadening DEA Drug Targeting Powers
• Corn Producers Get Class Cert. In Syngenta GMO MDL
• Fed. Circ. Says Carnitine Classified As Duty-Free
• Full Fed. Circ. Won't Eye Ruling On New AIA Review Evidence
• Cephalon Faces Pa. Suit Over Opioid Marketing After Death
• Docs Treating Opioid Addicts To Report Details To HHS
• Amgen Sues Actavis, Indian Cos. Over Sensipar Generics
• Judge Orders Depositions Of Ex-Forest Labs Employees
• Pregnancy Test Maker Asks 2nd Circ. To Rehear False Ad Row
• Third Time's Not The Charm For Opioid Painkiller At FDA
• Rankled Avon Users Ask 2nd Circ. To Reverse Class Denial
• PhRMA Rips Feds For 'Regulation By Litigation' On Kickbacks
• Alere Hit With New Complaint Over $5.8B Abbott Merger
• Pfizer Again Ditches Plan to Split Into 2 Businesses
• Pa. Judge Urged To Consolidate Philly Invokana Cases
• Bid To Pause PharmaCare Herbal Sex Pill Suit Comes Up Short
• You Don't Need A Data Breach To Face Regulatory Scrutiny
• GSK Still Wants Hearing On Expert Of Reed Smith Atty's Widow
• Mylan Asks High Court To Rule On Venue For ANDA Cases
• 3 Firms Prime IPOs Totaling $547M Led By 'Unicorn' Nutanix
• High Court Asked To Nix PTAB Power To Start AIA Reviews
• 2nd Circ. Says CoreLogic Doesn't Have To Pay $4M In FTC Suit
• FDA Approves Amgen's Humira Biosimilar
• Health Hires: BakerHostetler, Hinckley Allen, Ballard Spahr
• Rainmaker Q&A: Hogan Lovells' Alice Valder Curran
• J&J Invokana Suits Should Be An MDL, Patients Say
• Generic EpiPen Will Likely Secure Profits For Mylan
• FCC Fines Siemens $175K For Hiding FCPA Felonies
• Drug Cos. Tell 3rd Circ. To Affirm Eye Drop Suit Dismissal
• Seniors Urge 9th Circ. To Revive Suit Over Muscle Drink
• 35 States Sue Indivior In Antitrust Row Over Suboxone
• Medtronic Avoids Off-Label Spinal Fusion Device Suit
• Costco Fights 9th Circ. Appeal Over Apotex Drug's Origins
• GSK Exec Can't Dodge Whistleblower's Firing Suit
• Bayer Willing To Give Up $1.6B Yearly To Land Monsanto
• Senate GOP Pushes Gov't Funding Band-Aid, As Dems Balk
• Fed. Circ. Affirms J&J Win In Roche Blood Test Patent Case
• White & Case Snags Ex-Ropes & Gray IP Partner
• Pharmacist In $150M Drug Fraud Gets Up To 6 Years In Prison
• FTC Asks To Keep Lifewatch Execs On Hook In Phone Scam
• Ohio Attys Now Safe To Advise On Legal Marijuana Activity
• Free Speech No Defense In Fatal Meningitis Outbreak: Judge
• Teva, Apotex, Mylan Sued Over 'Extreme' Statin Prices
• Allergan Seeks Full 3rd Circ. Look At Eye Drop Antitrust Suit
• Practical Uses For Machine Learning In Health Care Cases
• Ex-Hospital CEO Says Attys' Prostitution Claim Defamed Him
• GNC, Supplement Cos. Get ThermoLife Amino Patents Nixed
• Ex-Hearing Aid Co. Execs Indicted For Embezzling $20M
• Biz Groups Back Aventis In 10th Circ. Label-Warning Fight
• House Committee Frustrated At Mylan CEO's Tight Lip
• Chancery OKs $24M Settlement In Caris Stock Option Dispute
• Fresenius Scores Preliminary Injunction In Drug Patent Case
• Hospital Consultant Seeks Quick Win In FCA Retaliation Suit
• Anthem, Cigna Both Claim Merger Breach, DOJ Says
• Latham-Led Tech Startup, Biotech IPOs Raise $129M
• Mass. Court Upholds Dismissal Of J&J Birth Control Suit
• Otsuka Sues Indian Pharma Cos. Over Planned Abilify Generic
• Land O'Lakes To Appeal Tainted Whey Suit Dismissal
• Rainmaker Q&A: Wolf Greenfield's Jason Honeyman
• Dow Not Warning Calif. Residents Of Pesticide Use, Suit Says
• Nu Skin Settles With SEC In China Charity-Donation Probe
• Ill. Judge Trims Claim From J&J Baby Powder Class Action
• Girardi Keese Nears Escape From $4.4M GSK Fee-Split Fight
• AstraZeneca IP Suit Survives Generics Co.'s Application Swap
• Senate Starts Stopgap Funding Debate, Details In Flux
• FDA Warning Wire: A New Cop On The E-Cig Beat
• Abbott Scores Fed. Circ. Win In 20-Year Yeda Patent Battle
• Overhauling Law Firm Records Departments For A New Reality
• 2nd Circ. Vitamin C Ruling A Landmark For Comity
• W.Va. AG Says Mylan Dodged EpiPen Subpoena
• Taylor-Wharton Wins Liquidating Ch. 11 Plan Confirmation
• Ex-Akebia Manager Pleads Not Guilty To Insider Trading
• Drug Cos. Pledge To Tackle Antibiotic Overuse, Pollution
• Big Pharma Backs Acclarent Execs In Off-Label Case
• Rainmaker Q&A: Holland & Knight's Jeffrey Mittleman
• Shire Prices $12.1B Bond To Help Pay For Baxalta Deal
• The Potential For Litigation In New Era Of Biosimilars
• Deals Rumor Mill: Bayer, Naspers, Rabobank
• Allergan Grabs Liver Disease Drugmaker In Up-To-$1.7B Deal
• $147M Award In Vitamin Antitrust Suit Vacated By 2nd Circ.
• Sanofi Hits Merck With Patent Suit Over New Diabetes Drug
• After Searing Debate, FDA Clears Unproven Sarepta Drug
• Supplement Co. Can't Ditch Claim It Rigged Amazon Reviews
• Quinn Emanuel Agrees To Duck Out Of Elan Investor Suit
• Gov't Band-Aid Funding Debate Stalled By Senate
• Ex-Kaye Scholer Atty In Shkreli Fraud Case Wants More Info
• Herbicide In Monsanto's Roundup 'Unlikely' To Cause Cancer
• Deals Rumor Mill: Bayer, BRF, Saudi Telecom
• Enviros Ask FDA To Withdraw Livestock Antibiotic Approvals
• PharmaCare Says No To Stay In Herbal Sex Pill Suit
• NuScience Renews Bid To Have Brothers Jailed In IP Row
• Judge OKs $486M Celebrex, Bextra Securities MDL Deal
• 'Unicorn' Nutanix Among 4 IPO Launches Totaling $543M
• GSK Lowers Cost Of Pneumonia Vaccine For Child Refugees
• In Congress: A Continuing Resolution?
• Shire Loses Patent Suit Against Zydus Over Generic Lialda
• GSK, Teva Drug Caused Child's Cancer, Parents Tell 9th Circ.
• 8 Firms To Guide IPOs Surpassing $1.1B Led By Valvoline
• German Cryo-Chamber Maker Wants Arbitration In €4M Row
• Roche Seeks To Toss Accutane Ulcerative Colitis Testimony
• Tucker Ellis Adds Six Attorneys In Chicago
• Fed. Circ. Upholds LifeNet's $35M Win In Graft Patent Suit
• Deals Rumor Mill: WhisperText, Depomed, Techem
• Marijuana Legalization Votes Won't End Drug-Free Workplaces
• Taxation With Representation: Sullivan, Wachtell, Jones Day
• Medical Supplier Says Safe Harbor Applied In FCA Row
• FDA Accuses 2 Drug Cos. Of Marketing Unapproved Opioid
• SynCardia's $19M Ch. 11 Sale To Lender Approved
• 3rd Circ. Asked To Reconsider Precedential Jurisdiction Order
• 2nd Circ. On Hunt For Antitrust Theory In $2B Takeda Action
• Apotex Takes Biosimilar Case To Supreme Court
• PharmaCare Stiffly Opposes Customer's Sex Pill Suit
• Health Funds Say Drug Cos. Fixed Skin Cream Prices
• IRS Slams Colo. Dispensary's Refund Bid In Pot Tax Suit
• Evidence Of Copying Is Irrelevant In Hatch-Waxman Cases
• Sen. Leahy On The AIA's 5th Anniversary
• Rep. Smith On The AIA's 5th Anniversary
• IP Fears Keep Life Sciences, Health Care GCs Up At Night
• Device Maker Looks To Nix Fired Worker's Suit Before Trial
• 2nd Circ. To Scrutinize Antitrust Causation In Actos Case
• Pfizer Faces Sanctions Bid In Suit Over Poultry Vaccine
• Deals Rumor Mill: McDonald's, BP, Apollo Global
• Judge Upset 'Entire Balance' Of Biosimilar Law, Amgen Says
• SEC's Spread Bet Argument Fails In Insider Trading Dispute
• Zimmer Knee MDL Shrinks Further Under Judge's Wary Eye
• New Mexico Sues Bristol-Myers For False Marketing Of Plavix
• Drug Cos. Would Have To Justify Price Hikes Under New Bills
• Nature's Way Bashes Ginkgo Pill Suit As Buyers Seek Cert.
• From Fapiao To Gestores: FCPA Risks In China, Latin America
• 3 Steps To Successful Judgment Enforcement
• Monsanto Denied Toss of Herbicide Cancer Lawsuit In Del.
• FDA Panels To Mull Opioid Painkillers In Children
• Fla. Pharmacy Owners To Pay $7.8M To Settle FCA Suit
• Judge Approves Asset Freeze In Roca Labs False Ad Suit
• UN Report On Public Health Access Blasted By Biz Groups
• 3rd Circ. Affirms Toss Of Atty's Fish-Oil Safety Suit
• Bayer's $66B Monsanto Buy To Face Tough Antitrust Scrutiny
• SAC Backs Push For Quinn Emanuel DQ In Elan Investor Suit
• IP Suit Over Amylin Drug Promos Timely, Justices Told
• Takeda Says 2nd Circ. Zanaflex Ruling Torpedoes Actos Row
• Supreme Court Urged To Revive OxyContin Patents
• Valeant Says Investors' Suit Is Based On Hindsight
• Abcodia Pulls Ovarian Cancer Screening Test On FDA Doubts
• Withers Guides Creation Of Trans-Atlantic Stem Cell Venture
• Fed. Circ. Erred On Patent Law Int'l Reach, Justices Told
• The Post-AIA Battleground For Patent Challenges
• Bayer Wins Over Monsanto With $66B Deal
• 3rd Circ. Pens Numerosity Rules In Provigil Antitrust Row
• Actavis Wants False Ad Claims Dismissed With Prejudice
• Gilead Attacks Post-Merger Claim to $50M Cancer Drug Bonus
• Nutraceutical Shakes Some Claims In 'Sugar Pill' Suit
• EU Court Writes Prescription For Pay-For-Delay Enforcement
• 1st Circ. Agrees Chemist's $5.6M Income Is Not Tax-Exempt
• FDA Warning Wire: 'Spore-Forming Bacteria' At Pharmacies
• GlaxoSmithKline Must Fight Paxil Cases In Delaware
• Loeb & Loeb Sees Ex-GC's Employment Suit Revived
• Vanda Wields New Labeling To Stymie Fanapt Generics
• IMS Plans $1.5B Bond To Help Finance $8.9B Quintiles Deal
• Pharma Co. Vendor Sues Over Exec's Departure To Rival
• Boston Scientific Pelvic Mesh Trial Win Overturned
• Deals Rumor Mill: Bayer, Postal Savings Bank Of China, Teneo
• FCA Relator Asks 9th Circ. To Revive Drug Kickbacks Case
• Calif. Says Bad Records Don't Let Taylor-Wharton Dodge Tax
• An End-Run Around Myriad And 'Product Of Nature' Problem
• Should Your Law Firm Move To The Cloud?
• Quinn Emanuel May Face DQ Action In SAC Capital Suit
• Ex-Warner Chilcott Worker Seeks Path To File Age Bias Suit
• Patients Stand By Claims Of Metal Debris In Brains
• Schwarzenegger Supplement Maker Rival Pumps Up Its Case
• Sanofi Kickback Claims Still Lacking, Dismissal Motions Say
• Fed. Circ. Remands Stryker Damages After High Court Ruling
• Nev. Stock Promoter Cops To $33M Pump-And-Dump Scheme
• FDA Concerned About Study On Risks Of Chantix
• Judge Won't Reconsider Globus Securities Suit Dismissal
• Kirby McInerney Named Lead Counsel In NJ Securities Row
• Par Pharmaceutical Says Escobar Nixes Gov't FCA Suit
• Teva Sues United To Enforce Provigil Antitrust Settlement
• Muscle Milk Consumers Seek Cert. In Labeling Suit
• UnitedHealth Cuts Drug, Alcohol Abstention For Hep C Meds
• Taro, Execs Receive DOJ Subpoenas Over Generic Drug Prices
• Quest Diagnostics Wins Appeal On La. Income Tax Refund
• From The Partner's Desk: Paving Your Path To Partnership
• Illumina Wins 'Rare' Early Ban On Rival's Product In IP Row
• Eli Lilly, Canada Fight For Fees In NAFTA IP Policy Row
• Del. Hemispherx Settlement Delayed By CEO's Fla. Case
• 5 Key Takeaways From The GPhA Biosimilars Forum
• Pfizer Didn't Disclose Viagra's Melanoma Risks, MDL Says
• No Proof Ovarian Cancer Screening Tests Work, FDA Warns
• Health Hires: Government Attorneys Join Covington, Foley
• Brand Battles: Dallas Cowboys Go After Youth Football Team
• Humana Overcharges Ill. Patients for HIV Drugs, DHS Told
• 2nd Circ. Backs Clearblue Pregnancy Test False-Ad Ruling
• Woman Convicted In Stolen Medical Device Scheme
• Ferring Gets Extra Exclusivity As Judge Reverses FDA Win
• 3rd Circ. Wellbutrin Case Could Guide Patent Settlements
• Sorrento Therapeutics Investor Says Board Looted Company
• Deals Rumor Mill: Bayer, CenturyLink, Samsung Electronics
• AstraZeneca And The SEC's Focus On Life Sciences
• How We Can Diversify The Legal Profession And Why We Must
• Masimo, Philips Argue For Quick Wins In Blood Sensor Fight
• UCB's Antibody Patent Win Against Yeda Backed By Fed. Circ.
• Euro Drug Pricing's Tradeoffs May Limit Appeal In US
• Boehringer, Teva Want Aggrenox Pay-For-Delay Claims Nixed
• Avexis' $147M Follow-On Offering Leads 2 Biotech Stock Deals
• Neovasc Fights Injunction Request In $70M IP Verdict
• Investor Class Suit Over Cancer Co. IPO Goes To Fed. Court
• Deals Rumor Mill: Bayer, Lone Star Funds, Shop-Apotheke
• Vitamin Health Asks 6th Circ. To Revive Coverage Battle
• Contact Lens Cases Might Bring Clarity To Antitrust Issues
• Feds Drop Case Against Ex-Va. Gov. McDonnell And His Wife
• Intercept's $55M Payout In Stock-Drop MDL Gets Final OK
• Patients Seek Revival Of Diabetes Drug Claims In 9th Circ.
• Buyer Must Give Up Suboxone Docs In Product-Hopping MDL
• Celgene Knocks Feds' Support Of $40B Off-Label FCA Suit
• 1st Circ. Panel Wary Of FCA Suit Against Medtronic Unit
• Johnson & Johnson, Kelly Services Lose FCRA Arbitration Bid
• Vaginal Mesh MDL Judge Sick And Tired Of Bogus Suits
• J&J Hit With More Talcum Powder Ovarian Cancer Claims
• Gilstrap Goof Requires Patent Verdict Fix, Device Co. Says
• Dentsply Urges Mass. High Court To Uphold Fraud Win
• Volcano Investors Appeal 'Radical' Chancery Court Ruling
• J&J Talc Suits Show Evidence Standards Vary Among Courts
• Med Equipment Cos. To Pay $12M To Settle FCA Allegations
• USPTO Fee Rule Upends 170 Years Of History, Fed Circ. Told
• Teva Asks Fed. Circ. To Nix Lilly's Chemo Patent Win
• Depositions Repetitive In Celexa, Lexapro MDL, Forest Says
• St. Jude Sues Over 'Defamatory' Cardiac Device Report
• Sidley Aids PE-Backed Microbiology Co. In Accuratus Lab Buy
• FDA Is Evolving On Qualifications For 'New Chemical Entity'
• Allergan Eye Drop Antitrust Suit Revived By 3rd Circ.
• Leveraging Trial Strategies To Improve Your Negotiating Skills
• Venable Adds Trial-Savvy IP Partner From Orrick
• FDA Warning Wire: Bausch & Lomb, Jazz Pharma, Pan Drugs
• Apotex Cleared Of Amgen Infringement Claims In Fla. Suit
• 3 Potential Claims Mylan Faces In EpiPen Drama
• Nixon Peabody Mistakes Cost Them $8M, Business Trio Says
• SEC Sues Penny Stock CEO Over Promotional Campaigns
• Bull Semen Sorting Row Needs New Trial, Supplier Says
• FTC Says Allergan Must Face Lidoderm Generic Delay Suit
• Danaher Grabs Molecular Diagnostics Co. In $4B Cash Deal
• SEC Rejects Ex-E&Y Partner's Oversight Board Challenge
• Old Skills, New Tricks: Opportunities For Law Librarians
• 1st Circ. Revives Suit Saying CVS Hawked Useless Vitamin E
• Agreement Doesn't Bar Seeger Vioxx Claims, 5th Circ. Hears
• NY To Investigate Mylan's EpiPen School Discounts
• Bayer Sweetens Bid For Monsanto To $127.50 Per Share
• CytRx Shareholders Get Del. Stock-Pump Suit Moving Again
• Mylan Persisted In Delaying EpiPen Generic, Study Says
• Fed. Circ. Erred On Patent Law's Reach Abroad, Justices Told
• Clinton Would Fight Drug Price Hikes With Imports, Fines
• Sanctions Denied As Wal-Mart Supplement False Ad Suit Ends
• Texas High Court Passes On Branch Law's Avandia Fee Fight
• Biotech Co. Escapes Stock Promotion Scheme Class Action
• Alice, Mayo Nix Some TB Test Patent Claims, Keep Others
• Disclose Execution Drug Supplier, 8th Circ. Orders Missouri
• FDA Bans Soap Antibacterial Agents With Potential For Harm
• CardiAQ Says $23M Is Minimum Fair Boost To $70M IP Verdict
• Acclarent Execs Say Their Convictions Violate 1st Amendment
• J&J Beats Pair Of Talcum Powder Ovarian Cancer Suits In NJ
• Alere, Abbott Told To Mull Mediation Before Merger Trial
• Will 'Dr. Bull' Affect Actual Jurors?
• Metal Hip Patient Asks 11th Circ. To Affirm $2M Defect Win
• Pfizer Stockholder Denied Request To Inspect Co. Records
• Pain Therapeutics Gets Nod On $8.5M Remoxy Class Deal
• Allergan OKs Generic Of Alzheimer's Drug Namzaric For 2025
• Feds Give Takeda $20M To Develop, Test Zika Vaccine
• CVS Agrees To Reform Opioid Dispensing Practices In Mass.
• Bayer Shakes Majority Of Essure Twin Pregnancy Suit
• Omnicare Asks To Appeal $421M FCA Suit To 1st Circ.
• Opioid Maker's Investors Say Co. Illegally Marketed Drug
• Senators Want Federal EpiPen Spending Data From CMS
• Foster Pepper, Barack Ferrazzano Steer $134M Seattle Deal